Management Team,  Board of Directors


Hidenobu Ishizaki President
Koji Tamada Director,  Chief Scientific and Medical Officer (CSMO)
Toyozo Goho Director
Hironari Hashioka Corporate Auditor   

Founding Team and Scientific  Advisory Board


Hidenobu Ishizaki, M.D., Ph.D.   Founder and President

 

Dr. Hidenobu Ishizaki is one of our co-founder and has served as our Chief Executive Officer. In 1996, Dr. Ishizaki received a M.D. from University of Miyazaki. He completed his internship and residency in surgery at Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, and his fellowship at Showa University Northern Yokohama Hospital. In 2007, he received Ph.D. from Graduate School of Medicine, The University of Tokyo. He developed antiangiogenic cancer vaccine targeting tumor endothelial cells, and it was conducted in multi-institutional clinical trials in Japan. After receiving license of Ph.D., Dr, Ishizaki was a postdoctoral research fellow at the Division of Translational Vaccine research and Department of General and Oncologic Surgery, City of Hope National Medical Center until 2010. He has over 7 years’ experience in vaccine development against cancer. After leaving City of Hope, he returned to University of Miyazaki Hospital as a colorectal surgeon. In 2015, Dr. Ishizaki founded Noile-Immune Biotech Inc. with his partners and collaborators to pursue novel cancer immunotherapy development.    

Koji Tamada, M.D., Ph.D.   Founder

Professor, Department of Immunology, Yamaguchi University Graduate School of Medicine

Professor, Center for Gene and Cell Therapy, The Institute of Medical Science, The University of Tokyo

 

After graduating from Kyushu University School of Medicine, Dr. Tamada acquired a Ph. D. in cancer immunology research. He then traveled to the United States and has engaged in R&D (research and development) for state-of-the-art cancer immunotherapy for the next 13 years. After devoting himself to study at Dr. Lieping Chen's research laboratory at Mayo Clinic's department of immunology, he gained independence at Johns Hopkins University as an assistant professor. He later became the leader of the basic research department for the cancer immunotherapy program at Maryland State University's Cancer Center. He has performed cloning and functionality analysis of PD-L1 (B7-H1) with Dr. Lieping Chen, and contributed to the application of cancer immunotherapy with immune checkpoint inhibition. He is currently actively advancing the development of functional control technology of immune-related molecules and the development of new cancer immunotherapy using genetically modified technology.

Kiyoshi Yoshimura, M.D., Ph.D., M.O.T.   Founder

Chief director, Division of Cancer Immunotherapy, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center

 

After graduating from Yamaguchi University School of Medicine, Dr. Yoshimura entered the Surgery II program (currently the Department of Digestive Surgery and Surgical Oncology) of the same school. He acquired his Ph. D. by studying the development of cancer immune gene therapy at the graduate school of Yamaguchi University through a related hospital. Yoshimura then began researches as a postdoctoral fellow under Dr. Drew Pardoll and Dr. Richard Schulick at Johns Hopkins University, later becoming an assistant professor and returning home to Japan where he found his current job through Yamaguchi University. He has so far been involved in the development of immunotherapy with genetically modified listeria, combination antibody therapy with PD-1 and PD-L1, PD-L2 targeted therapy, complex therapy with GVAX, organ-specific immunotherapy, cancer stem cell target immunotherapy, and the development of a tumor immunity model using immunological humanized mouse. He also studies technology management studies such as intellectual property as a mature-aged student, patent value calculation, project management, venture business theory, and game theory.

Satoshi Wada, M.D., Ph.D.   Founder

Vice director, Division of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute

 

After graduating from Gunma University School of Medicine, Dr. Wada entered the Surgery I program (currently the Department of General Surgical Science) of the same school and studied digestive organ, liver, gallbladder and pancreatic surgery. After entering the graduate school of the same school through a related hospital, he gained his Ph. D. researching cancer immunotherapy at The Institute of Medical Science, The University of Tokyo. He then conducted researches as a postdoctoral fellow under Dr. Drew Pardoll and Dr. Charles Drake at John Hopkins University and worked as an assistant professor at Gunma University after returning to Japan until his current job. He has been involved in the development of new cancer vaccine therapy targeting new blood vessels and composite immunotherapy based on GM-CSF-producing cancer vaccines. He has further worked on the development of combination antibody therapy using anti-CTLA-4 and LAG-3 antibodies, combination therapy with cancer immunotherapy and radiotherapy, cancer stem cell target immunotherapy, and the identification of new cancer antigens in patient cancer tissue using immunodeficient mouse (NOG mice).

Tetsuya Nakatsura, M.D., Ph.D.

Chief director, Division of Cancer Immunotherapy, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center

Yukimi Sakoda, M.D., Ph.D.

Assistant Professor, Department of Immunology, Yamaguchi University Graduate School of Medicine

Richard D. Schulick, M.D., M.B.A, FACS.

Professor & Chair of Surgery, University of Colorado School of Medicine